Effect of the Tyrosine Kinase Inhibitor Nilotinib in Patients with Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia: Analysis of the Phase 2 Open-Label Single-Arm A2101 Study

摘要

PurposeHypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL) are characterized by sustained overproduction of eosinophils and organ dysfunction. CEL involves the presence of clonal genetic markers, such as a fusion of FIP1-like 1 protein and platelet-derived growth factor receptor α (FIP1L1-PDGFRα, or F/P) or PDGFRα-activating mutations.